Articles related to LIVER CANCER

The assessment of response to radiation-based therapies can be complicated by persistent or changing imaging features, and this field of study is still in active development even though imaging-based response assessment systems have been validated for the evaluation of response to ablative locoregional therapies. Research is still needed to address the shortcomings of current imaging criteria for evaluating tumor response to these novel techniques, despite the increased application of radiation-based local-regional therapies for the treatment of HCC following technological advancements and a better understanding of tumor biology.

The authors reasoned that stereotactic body radiation therapy (SBRT) followed by sorafenib would increase overall survival (OS) in advanced HCC compared to sorafenib alone, despite it being the standard of care. Despite immunotherapy replacing chemotherapy as the systemic norm after the trial’s enrollment period ended, the results were in. In the trial, 177 patients were randomly assigned to receive either sorafenib alone or SBRT followed by sorafenib. Prior to sorafenib administration, SBRT treatment markedly increased OS as well as the effectiveness of secondary goals like progression-free survival and time to progression.

Doctors and other healthcare professionals should be better able to describe the current role of immuno-oncology (IO) in patients with hepatocellular carcinoma (HCC) and evaluate how new information on novel IO strategies may alter the approach to therapy in HCC after completing this four-chapter CME activity.

Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?

The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.

In patients with NETs with distant metastasis, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits are scarce. The authors purposed to analyze the use of 90Y RE in NET patients with hepatic metastases in an international, multicenter retrospective analysis. In reviewing response data, they conclude that 90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.